Please assess the completion status of the following clinical trial:

Trial Title: Dextromethorphan in Treating Patients With Fatigue Caused by Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of malignancy~  * Must be undergoing active treatment for malignancy which may include hormonal therapy (e.g., tamoxifen citrate or leuprolide acetate), but not radiotherapy alone~* Fatigue score ≥ 4 on a verbal analogue scale of 0 to 10~* No untreated cancer-related anemia~PATIENT CHARACTERISTICS:~* Hemoglobin \> 10 g/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to swallow pills~* No known allergy to dextromethorphan hydrobromide~* No patients known to be phenotypically poor metabolizers of CYP2D6~* No untreated hypothyroidism~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior single-dose inhibitors (e.g., ranitidine or cimetidine) for hypersensitivity prophylaxis allowed~* Erythropoietic growth factor therapy of \> 8 weeks duration allowed~* No concurrent CYP2D6 inducers or inhibitors~* No concurrent monoamine oxidase inhibitors~* No other concurrent medications containing dextromethorphan hydrobromide~* No concurrent over-the-counter medication, herbal product, vitamin, food supplement, or any other type of special product unless permission to continue use is obtained from the Principal Investigator~* No other concurrent anticancer investigational agents or therapies

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).